ProQR Therapeutics NV has 12 Schedule 13D or 13G filings on record since 2025-08-12. 5 holders' latest filing reports 5% or more of ordinary shares, nominal value eur0.04 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ELI LILLY & Co | 15.6% | 21,995,880 | SCHEDULE 13G/A, 2026-07-24 | 2026-06-26 |
| Van Herk Investments B.V. | 10.9% | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 | 2026-07-27 |
| Aberdeen Group plc | 6.33% | 8,932,507 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Adage Capital Management, L.P. | 6.27% | 6,601,938 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Patrick Johan Hendrik Krol | 5.2% | 5,528,862 | SCHEDULE 13G/A, 2026-07-15 | 2026-07-15 |
Purpose of Transaction (Item 4)
Van Herk Investments B.V.
Item 4 of the Schedule 13D is amended by adding the following: On July 27, 2026, the Reporting Persons filed a petition (the "Petition") with the Enterprise Chamber (Ondernemingskamer) of the Amsterdam Court of Appeal against the Issuer, pursuant to Article 2:345 of the Dutch Civil Code and including a request for immediate relief measures pursuant to Article 2:349a(2) of the Dutch Civil Code. The Petition requests that the Enterprise Chamber (i) order an investigation into the policies and conduct of affairs of the Issuer from May 22, 2024 to the present, based on alleged systematic deviations by the Issuer's board of directors from the Issuer's own governance framework and applicable governance standards, including with respect to the reappointment of certain directors, the composition and independence of the board and its committees, and director compensation, and (ii) as an immediate relief measure, appoint an independent non-executive director to the Issuer's board of directors pending the outcome of the investigation. The foregoing description of the Petition does not purport to be complete and is qualified in its entirety by reference to the full text of the English translation of the Petition, which is filed as Exhibit 99.2 hereto and incorporated herein by reference. The Reporting Persons reserve all rights to pursue any and all available legal remedies against the Issuer, members of the board of directors and/or certain officers of the Issuer, and continue to …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-29; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 6.27% | SCHEDULE 13G/A |
| 2025-08-20 | Van Herk Investments B.V. | 11.6% | SCHEDULE 13D/A |
| 2025-09-04 | Van Herk Investments B.V. | 12.6% | SCHEDULE 13D/A |
| 2025-09-30 | Van Herk Investments B.V. | 13.6% | SCHEDULE 13D/A |
| 2026-01-20 | Privium Fund Management B.V. | 5.2% | SCHEDULE 13G |
| 2026-02-06 | Van Herk Investments B.V. | 14.6% | SCHEDULE 13D/A |
| 2026-06-03 | Van Herk Investments B.V. | 14.6% | SCHEDULE 13D/A |
| 2026-06-30 | Van Herk Investments B.V. | 10.9% | SCHEDULE 13D/A |
| 2026-07-15 | Patrick Johan Hendrik Krol | 5.2% | SCHEDULE 13G/A |
| 2026-07-24 | ELI LILLY & Co | 15.6% | SCHEDULE 13G/A |
| 2026-07-29 | Van Herk Investments B.V. | 10.9% | SCHEDULE 13D/A |
| 2026-07-29 | Aberdeen Group plc | 6.33% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for ProQR Therapeutics NV. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.